HomeInsightsStock Comparison

Alivus Life Sciences Ltd vs Venus Remedies Ltd Stock Comparison

Alivus Life Sciences Ltd vs Venus Remedies Ltd Stock Comparison

Last Updated on: Aug 02, 2025

Key Highlights

  • The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1001 as of 01 Aug 15:30.
  • The P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2020 to 0 on March 2025 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Venus Remedies Ltd changed from 5.5 on March 2021 to 8.8 on March 2025 . This represents a CAGR of 9.86% over 5 years.
  • The Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Venus Remedies Ltd changed from ₹ 27.77 crore on March 2020 to ₹ 400.47 crore on March 2025 . This represents a CAGR of 56.01% over 6 years.
  • The revenue of Alivus Life Sciences Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Venus Remedies Ltd for the Jun '25 is ₹ 140.59 crore as compare to the Mar '25 revenue of ₹ 201.73 crore. This represent the decline of -30.31%.
  • The ebitda of Alivus Life Sciences Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Venus Remedies Ltd for the Jun '25 is ₹ 18.79 crore as compare to the Mar '25 ebitda of ₹ 35.76 crore. This represent the decline of -47.46%.
  • The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Venus Remedies Ltd changed from ₹ 1.18 crore to ₹ 9.6 crore over 9 quarters. This represents a CAGR of 153.87% .
  • The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Venus Remedies Ltd changed from 0 % on March 2020 to 0 % on March 2025 . This represents a CAGR of 0.0% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alivus Life Sciences Ltd

  • Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
  • The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Venus Remedies Ltd

  • Incorporated in 1989 Venus Remedies Ltd (formerly known Venus Glucose Pvt Ltd), was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited.
  • The Company was promoted and managed by Chaudhary & Family.
  • The Company is one of the handful player in pharmaceutical sector to launch injectables globally.
  • It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India).
  • In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc. The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana.

Alivus Life Sciences Ltd News Hub

News

Alivus Life Sciences to declare Quarterly Results

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 1 Aug...

Read more

25 Jul 2025 11:06

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBIT...

Read more

23 Jan 2025 15:01

News

Alivus Life Sciences Ltd leads gainers in 'A' group

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are amon...

Read more

21 Jan 2025 12:00

Venus Remedies Ltd News Hub

News

Venus Remedies to table results

Venus Remedies will hold a meeting of the Board of Directors of the Company on 1 August 20...

Read more

23 Jul 2025 09:51

News

Venus Remedies to hold AGM

Venus Remedies announced that the 36th Annual General Meeting(AGM) of the company will be ...

Read more

10 Jul 2025 09:50

News

Venus Remedies to conduct board meeting

Venus Remedies will hold a meeting of the Board of Directors of the Company on 8 July 2025...

Read more

27 Jun 2025 16:28

News

Venus Remedies spurts after Q4 PAT climbs 100% YoY to Rs 21 cr

However, revenue from operations decreased marginally to Rs 194.97 crore in Q4 FY25, as ag...

Read more

27 May 2025 11:37

News

Venus Remedies to hold board meeting

Venus Remedies will hold a meeting of the Board of Directors of the Company on 26 May 2025...

Read more

17 May 2025 16:57

News

Venus Remedies jumps as investigational drug secures QIDP tag from USFDA

The drug is intended for the treatment of bloodstream infections caused by polymyxin B (PM...

Read more

17 Apr 2025 10:23

SWOT Analysis Of Venus Remedies Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

BlinkX Score for Venus Remedies Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alivus Life Sciences Ltd and Venus Remedies Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Venus Remedies Ltd?

Market cap of Alivus Life Sciences Ltd is 12,278 Cr while Market cap of Venus Remedies Ltd is 700 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Venus Remedies Ltd?

The stock performance of Alivus Life Sciences Ltd and Venus Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Venus Remedies Ltd?

As of August 2, 2025, the Alivus Life Sciences Ltd stock price is INR ₹1001.25. On the other hand, Venus Remedies Ltd stock price is INR ₹524.0.

How do dividend payouts of Alivus Life Sciences Ltd and Venus Remedies Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Venus Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions